ESR1 and breast cancer: There is no clinically-proven type-specific therapeutic target for the 10% of breast cancer cases that are negative for ER, PR, and HER2, and hence are designated “triplenegative,” and only genotoxic chemotherapy is utilised (Sørlie et al., 2001).